Cerus Corp

CERS remains in a Stage 2 advancing uptrend, preserving higher highs above the rising 50 DMA. However, recent rejection at the 9 and 21 EMAs and a short-term downtrend suggest timing is unfavorable now. A pullback toward the rising EMAs or the 50 DMA support region would present a higher-probability entry opportunity.

• ↑Product revenue +24% YoY to $53.7M; full-year guidance lifted to $227–231M
• ↑Agreement with Blood Centers of America expands reach to half of U.S. supply
• ↓Gross margin fell to 52% from 58.8% YoY, squeezing profit margins